This report identifies the global penile cancer treatment market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global penile cancer treatment market.
Geographically North America dominated global penile cancer treatment market due to higher prevalence of penile cancer, and availability of affordable drugs. Asia Pacific is projected to have fastest growth, owing to rapidly increasing population, poor hygiene standards, and higher presence of a large HIV patient population in developing nations such as China, and India in this region. Among all the penile cancer type, squamous cell carcinoma type has the highest market share in global penile cancer treatment market.
This report segments global penile cancer treatment market on the basis of cause, penile cancer type, treatment, and regional market as follows:
Penile Cancer Treatment Market, By Cause: Human Papiloma Virus (HPV), and Human Immunodeficiency Virus (HIV)
Penile Cancer Treatment Market, By Penile Cancer Type: Squamous Cell Carcinoma, Intraepithelial Neoplasia, Bowenoid Papulosis, and Invasive Carcinoma
The report has focused study on penile cancer treatment market by basis of treatment such as: Chemotherapy, Antiviral Therapy, and Surgical Excision
This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region
This report identifies all the major companies operating in the penile cancer treatment market. Some of the major companies’ profiles in detail are as follows:
MercK & Co
Mevion Medical Systems, Inc.
Varian Medical Systems, Inc.
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
2. Executive Summary
3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis
4. Penile Cancer Treatment Market– Market Forces
4.1.1. Development of efficient and advance treatment technology
4.1.2. Rise in the awareness among people about penile cancer and its treatment
4.1.3. Increase in population of penile cancer patient
4.2.1. Higher cost of treatment, and research and development
4.2.2. Unavailability of affordable diagnostic procedures and therapeutic drugs
4.3.1. Emerging economies
4.3.2. Increase in adoption of penile cancer treatment
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition
5. Penile Cancer Treatment Market– Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors
6. Penile Cancer Treatment Market, By Cause
6.1. Human Papiloma Virus (HPV)
6.2. Human Immunodeficiency Virus (HIV)
7. Penile Cancer Treatment Market, By Penile Cancer Type
7.1. Squamous Cell Carcinoma
7.2. Intraepithelial Neoplasia
7.3. Bowenoid Papulosis
7.4. Invasive Carcinoma
8. Penile Cancer Treatment Market, By Treatment
8.2. Antiviral Therapy
8.3. Surgical Excision
9. Penile Cancer Treatment Market, By Geography
9.1.7. Rest of Europe
9.2. Asia Pacific
9.2.4. South Korea
9.2.5. Rest of Asia-Pacific
9.3. North America
9.4. Rest of the World (RoW)
9.4.2. Rest of RoW
10. Penile Cancer Treatment – Market Entropy
10.2. Technological Developments
10.3. Merger & Acquisitions, and Joint Ventures
10.4. Supply- Contract
11. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
11.1. GlaxoSmithKline PLC
11.2. Novartis AG
11.3. MercK & Co
11.4. Mevion Medical Systems, Inc.
11.5. Varian Medical Systems, Inc.
11.6. Elekta AB
11.7. Accuray Incorporated
11.8. Nordion, Inc.
11.9. C. R. Bard, Inc.
11.10. Raysearch Laboratories AB
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
12.3. Research Methodology
12.5. Compilation of Expert Insights